A phase 1/2 study evaluating safety, tolerability and preliminary efficacy of EPI-7386 in combination of Apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed a current second-generation antiandrogen therapy
Latest Information Update: 24 Jan 2022
At a glance
- Drugs Apalutamide (Primary) ; Masofaniten (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2022 According to an ESSA Pharma media release, this study is expected to start in 2022.
- 11 Feb 2021 According to an ESSA Pharma media release, the company expect to initiate this trial in 2021.
- 20 Jan 2021 New trial record